National Bank of Canada
ALLO icon

National Bank of Canada’s Allogene Therapeutics ALLO Stock Holding History

National Bank of Canada’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$999 Sell
411
-89
-18% -$178 ﹤0.01% 2673
2025
Q4 		$680 Hold
500
– – ﹤0.01% 2666
2025
Q3 		$615 Buy
500
+33
+7% +$39 ﹤0.01% 2679
2025
Q2 		$527 Buy
+467
New +$621 ﹤0.01% 2761

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada's ALLO Position: Q1 2026 in Review

National Bank of Canada reduced its Allogene Therapeutics (ALLO) stake by 18% in Q1 2026, selling an estimated $178 and leaving 411 shares worth $999. The position accounts for ﹤0.01% of the portfolio, ranked #2673.

National Bank of Canada first reported a position in ALLO in Q2 2025 and has held it in 4 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • National Bank of Canada held 411 shares of Allogene Therapeutics worth $999 as of Q1 2026.
  • National Bank of Canada sold 89 Allogene Therapeutics shares in Q1 2026, an estimated $178.
  • Allogene Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2673 holding.
  • National Bank of Canada first reported a position in Allogene Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.